Kainate receptors (KARs) are heteromeric glutamate-gated ion channels that regulate neuronal excitability and network function in the brain. Most KARs contain the subunit GluK2 and the precise properties of these GluK2-containing KARs are determined by additional factors including ADAR2-mediated mRNA editing of a single codon that changes a genomically encoded glutamine (Q) to arginine (R) in the pore-lining region of GluK2. ADAR2-dependent Q/R editing of GluK2 is dynamically regulated during homeostatic plasticity (scaling) elicited by suppression of synaptic activity with TTX. Here we show that TTX decreases levels of ADAR2 by enhancing its proteasomal degradation. This selectively reduces the numbers of GluK2 subunits that are edited and increases the surface expression of GluK2-containing KARs. Furthermore, we show that partial ADAR2 knockdown phenocopies and occludes TTX-induced scaling of KARs. These data indicate that activity-dependent regulation of ADAR2 proteostasis and GluK2 Q/R editing provides a mechanism for KAR homeostatic plasticity.
Introduction
Kainate receptors (KARs) are ionotropic glutamate receptors that are tetrameric assemblies composed of combinations of five receptor subunits, GluK1-5 (1, 2) . KARs can be located pre-, postand/or extrasynaptically, where they contribute to neurotransmitter release, postsynaptic depolarisation and the regulation of neuronal excitability (3) . The variety of possible subunit combinations and co-assembly with Neto auxiliary subunits (4) , creates a wide range of possible KAR subtypes, with receptors containing GluK2 and GluK5 being the most abundant (3) .
Additional diversity of GluK2 containing KARs arises from RNA editing of GluK2 (5, 6 ) by the nuclear ADAR2 enzyme which edits pre-mRNAs encoding GluK2 and GluK1, as well as the AMPAR subunit GluA2, and other non-coding RNAs (7, 8) . ADAR2 mediated Q/R editing in the pore-lining region of GluK2 alters a genomically encoded glutamine residue to an arginine, changing both the calcium permeability and biophysical properties of the KARs. More specifically, GluK2(R) shows markedly reduced tetramerisation leading to its accumulation in the ER (9) . Furthermore, assembled GluK2(R)-containing KARs that do reach the plasma membrane are calcium impermeable and have a channel conductance of less than 1% of non-edited GluK2(Q)-containing KARs (10) .
ADAR2 levels are very low during embryogenesis but increase in the first postnatal week (11) to edit ~80% of GluK2, ~40% of GluK1 and ~99% of GluA2 subunits in the mature brain (12) (13) (14) . ADAR2 knockout mice die at the early postnatal stage, but can be rescued by expressing the edited form of GluA2, demonstrating that unedited AMPARs are fatally excitotoxic (15) . In contrast, mice specifically deficient in GluK2 Q/R editing are viable but are seizure prone and adults display an aberrant form of NMDAR-independent long term potentiation (LTP) (16) , demonstrating the importance of GluK2 editing to network function and synaptic plasticity.
NMDARs, AMPARs and KARs have all been shown to play roles in synaptic plasticity and their dysregulation is a prominent feature of cognitive decline in aging and neurodegenerative diseases (17) . LTP and LTD (long-term depression) enhance or decrease the efficiency of synaptic transmission, respectively, and are primarily mediated by changes in the number and properties of AMPARs at the postsynaptic membrane. 'Classical' LTP requires the activation of NMDARs (18, 19) .
However, recent data from our lab has demonstrated a novel role for KARs as critical inducers of one form of LTP (KAR-LTPAMPAR) (20) . Moreover, in addition to directly inducing synaptic plasticity of AMPARs, KARs themselves are plastic and undergo LTD (21) and LTP (22-24).
The assembly and progression of GluK2-containing KARs through the secretory pathway is controlled by a series of activity regulated checkpoints (25). Furthermore, chronic suppression of synaptic activity with TTX 'up-scales' KAR surface expression (25) . Homeostatic plasticity (scaling) of AMPARs and NMDARs is essential for normal neuronal network and brain function because it constrains neuronal firing to within a tunable physiological range (26-28). The discovery of KAR scaling is important because regulation of the number of surface expressed KARs will be a critical factor for induction of KAR-LTPAMPAR, and therefore constitutes a key regulator of synaptic transmission and neuronal excitability. However, how KAR scaling occurs mechanistically is unclear.
Here we show that chronic suppression of network activity with TTX leads to the proteosomal degradation of ADAR2. This, in turn, reduces editing of GluK2 pre-mRNA with a consequent increase in unedited GluK2, thus enhancing homomeric KAR assembly, ER release and surface expression.
Importantly, this up-scaling mechanism is specific to GluK2 as TTX did not change the editing status of GluA2. Together these data demonstrate a novel and selective role of mRNA editing by ADAR2 in homeostatic plasticity of KARs.
Results
Chronic suppression of network activity with TTX increases surface levels of GluK2-containing KARs Chronic TTX treatment increases AMPAR surface expression and AMPAR excitatory postsynaptic currents (EPSCs) (reviewed in (29)). Surface levels of GluK2 containing KARs also upscale in response to TTX treatment (25). Consistent with this, we show robust scaling of both KAR ( Figure   1A ,B) and AMPAR subunits ( Figure 1A,C) . In contrast, epidermal growth factor receptor (EGFR), which is widely expressed at synapses (30), was not affected by TTX ( Figure 1A,D) . Intriguingly, TTX-mediated suppression of synaptic activity treatment also reduced GluK2 Q/R editing ( Figure   1E ,F) but did not affect Q/R editing of the AMPAR subunit GluA2 (SI Figure 1A ,B,C). These findings suggest that KAR, but not AMPAR, up-scaling by TTX treatment may be mediated by decreased levels of GluK2 Q/R editing.
Chronic suppression of network activity with TTX decreases ADAR2 levels
We next tested the effects of chronic suppression of network activity on ADAR2 levels. Incubation with TTX for 24 h decreased ADAR2 levels by ~50%, but ADAR1 levels were unaffected (Figure 2A-D) . Interestingly, longer periods of TTX treatment did not decrease ADAR2 levels any further ( Figure   2E ,F), suggesting that a basal level of ADAR2 is retained even under long-term suppression of synaptic activity. As expected, the decrease in ADAR2 following 24 h TTX treatment occurs in the nucleus ( Figure 2G,H) , where ADAR2 binds to the GluK2 pre-mRNA prior to mRNA splicing and maturation (31). Moreover, both the intensity of ADAR2 signal and the percentage of ADAR2 expressing cells decreased significantly following 24 h TTX treatment ( Figure 2I ,J,K).
Complete and partial ADAR2 knockdown differentially alter GluK2 and GluA2 Q/R editing To further examine the role of ADAR2 in KAR scaling we generated two different shRNAs against ADAR2. One shRNA we named shRNA'Complete' ablated essentially all ADAR2 whereas another shRNA that we called shRNA'Partial', reduced ADAR2 levels to ~50% of the control ( Figure 3A,B) , comparable to the loss observed with TTX. Furthermore, shRNA'Partial' knockdown reduced the intensity of signal and percentage of cells expressing ADAR2 to levels similar to those elicited by TTX treatment (Figure 3C ,D,E).
We next compared how ADAR2 knockdown affected GluK2 and GluA2 editing. As expected, shRNA'Complete' ADAR2 knockdown reduced GluK2 Q/R editing by over 60%, whereas shRNA'Partial' knockdown of ADAR2 only reduced GluK2 Q/R editing by ~20% ( Figure 4A,B) . DNA sequencing chromatographs from cDNA of cells treated with shRNA'Complete' show a dramatic change in the base read of the editing site to CAG (Q) rather than CGG (R), whereas neurons treated with shRNA'Partial'
show a mixture of both CGG and CAG ( Figure 4C ). Interestingly, shRNA'Partial' knockdown of ADAR2 had no effect on the Q/R editing of the AMPAR subunit GluA2 while the shRNA'Complete' knockdown only reduced GluA2 editing by ~30% ( Figure 4D ,E,F). These data indicate that GluK2 editing levels are uniquely sensitive to ADAR2 changes and support a model whereby loss of ADAR2 during homeostatic scaling directly promotes surface expression of GluK2 containing KARs through a reduction in GluK2 editing.
Partial ADAR2 knockdown phenocopies and occludes TTX upscaling of GluK2 containing KARs Intriguingly, shRNA'Partial' reduces ADAR2 to levels comparable to those following TTX treatment and results in a similar shift in the proportions of edited to unedited GluK2. We therefore wondered if shRNA'Partial' alone is sufficient to mediate KAR upscaling. Partial ADAR2 knockdown significantly increased GluK2 surface expression with no effect on EGFR surface expression ( Figure 5A ,B,C), indicating that reduced levels of ADAR2 result in upscaling GluK2 containing KARs in the absence of TTX treatment. TTX treatment in combination with shRNA'Partial' knockdown was not additive ( Figure 5A ,B) consistent with TTX induced upscaling being mediated by a reduction in ADAR2 levels.
In shRNA'Partial' ADAR2 knockdown neurons, 24 h TTX treatment did elicit a further decrease in ADAR2 levels (SI Figure 2A .B), indicating that even when already depleted, ADAR2 levels are still subject to activity-dependent regulation. However, despite the summative decrease in ADAR2 levels, shRNA'Partial' ADAR2 knockdown combined with TTX treatment did not further decrease GluK2 Q/R editing compared to either treatment alone ( Figure 5D ,E). These data indicate that loss of ADAR2 is sufficient to mediate TTX induced up-scaling of KARs.
Loss of ADAR2 during scaling is not dependent on its interaction with Pin1
The nuclear protein Pin1 retains ADAR2 in the nucleus and interfering with this allows ADAR2 export to the cytosol, its ubiquitination and degradation (32). Our RT-qPCR experiments show that total ADAR2 mRNA levels are unaffected by TTX, indicating that scaling is not transcriptionally mediated (SI Figure 3) . We therefore wondered if destabilising the Pin1-ADAR2 protein interaction underpins ADAR2 loss by TTX but Pin1 levels were unchanged following TTX treatment ( Figure 6A,B) .
We next investigated the role of ADAR2 phosphorylation at threonine 32 (T32) in regulating ADAR2 levels during scaling, since this has been reported to crucial for the ADAR2-Pin1 interaction (32). In contrast to WT and phosphonull (T32A) ADAR2, the phosphomimetic (T32D) ADAR2 mutant binds very strongly to Pin1 in GFP-trap assays ( Figure 6C,D) . We therefore tested if the phosphonull or phosphomimetic ADAR2 mutants were more sensitive to TTX treatment. We first knocked down endogenous ADAR2 and replaced it with HA-tagged WT ADAR2 (SI Figure 4A,B) . More than 80% of the cells expressed the knockdown-rescue, similar to the percentage of untreated neurons that express ADAR2 (SI Figure 4A,B) . We then investigated the stability of the phosphonull or phosphomimetic ADAR2 mutants in response to TTX treatment. Similar to WT ADAR2, levels of both mutants were significantly decreased by TTX treatment (Figure 6E ,F; SI Figure 5 ). Furthermore, nuclear levels of all the constructs decreased following TTX treatment (SI Figure 6A,B) . Thus, activity-dependent untethering of ADAR2 from Pin1 is not a primary mechanism responsible for the loss of ADAR2 during TTX mediated upscaling.
TTX mediated scaling enhances proteasomal degradation of ADAR2
It has been proposed that ADAR2 is ubiquitinated and degraded in the cytosol (32). We therefore tested the effects of TTX on ADAR2 stability in the presence or absence of the proteasomal inhibitor Bortezomib (BTZ) (33). Consistent with suppression of synaptic activity leading to enhanced proteasomal degradation, BTZ prevented TTX-evoked decreases in ADAR2 ( Figure 7A ,B) and resulted in the accumulation of ubiquitinated products ( Figure 7A ,C). We next performed nuclear and cytoplasmic fractionations to determine if ADAR2 is exported from the nucleus for degradation in the cytosol. BTZ prevented the TTX-evoked decrease in ADAR2 in both the nuclear and cytosolic fractions, and actually led to a significant accumulation of ADAR2 in the cytosol ( Figure 7D ,E,F).
Thus, ADAR2 may be exported to the cytosol to be ubiquitinated or ubiquitinated in the nucleus and exported to the cytosol to be degraded. In either case TTX induces proteasomal degradation of ADAR2.
Blocking ADAR2 degradation prevents KAR up-scaling in response to TTX Since BTZ prevents the loss of ADAR2 in the nucleus in response to TTX, we next tested if preventing ADAR2 degradation with BTZ blocks TTX up-scaling of GluK2. Indeed, surface biotinylation showed that BTZ prevents TTX-induced GluK2 upscaling ( Figure 8A ,B) with no effect on EGFR ( Figure 8A,C) . These results support the hypothesis that ADAR2 degradation mediates KAR up-scaling.
Discussion
Selective ADAR2 mediated Q/R editing of GluK2 containing KARs regulates up-scaling Similar to AMPARs and NMDARs, GluK2 containing KARs up-scale following chronic suppression in synaptic activity (25). Here we show that the same TTX treatment leads to proteasomal degradation of ADAR2 and, consequently, reduced Q/R editing of GluK2. These data are consistent with activity-dependent loss of ADAR2 leading to the alteration in KAR editing which, in turn, directly mediates KAR up-scaling via increased KAR assembly and ER exit of unedited GluK2(Q) compared to edited GluK2(R) (9, 25) .
Partial ADAR2 knockdown mimicked the decrease in ADAR2 levels observed after TTX scaling and did not alter GluA2 editing. We therefore used this tool to further study the role of ADAR2 in GluK2 up-scaling. Partial loss of ADAR2 phenocopies and occludes TTX-mediated GluK2 editing and upscaling. Thus, loss of ADAR2 is sufficient to up-scale KARs in the absence of TTX, and strongly suggests that reduced KAR editing underpins KAR up-scaling ( Figure 9 schematic).
Differential sensitivity of GluK2 to changes in ADAR2 levels
While we observed robust up-scaling of both KARs (GluK2) and AMPARs (GluA2) by TTX, the mechanisms are different because the Q/R editing status of GluA2 was not altered. In line with this, complete loss of ADAR2 decreased GluA2 editing by ~30% and GluK2 editing by >60%, whereas partial ADAR2 loss decreased editing of GluK2 by ~20% but had no discernible impact on GluA2 editing. Notably, it has been reported that ADAR2 regulation of GluA2 is specifically confined to CA1 hippocampal and does not occur in CA3 (34). GluA2 is preferentially and almost completely Q/R edited, even when only low levels of ADAR2 are available. GluK2 mRNA, on the other hand, is more sensitive to changes in the levels of ADAR2. We interpret these data to indicate that the Q/R editing of KARs is more dynamically and activity-dependently regulated than AMPARs, and reason that this provides a rapidly tunable system to control KAR forward trafficking and scaling.
Activity dependent regulation of ADAR2 proteostasis during TTX treatment ADAR2 acts in the nucleus where it is stabilised by Pin1. Loss of the ADAR2-Pin1 interaction leads to ADAR2 export into cytosol where it is ubiquitinated and degraded (32). Pin1 mediated stabilisation is important for ADAR2 editing activity during development in cortical neurons (11) . However, our experiments suggest Pin1-ADAR2 interactions do not play a role in TTX up-scaling since both phosphonull and phosphomimetic mutants of ADAR2, which decrease or enhance binding to Pin1 respectively, were equally susceptible to the TTX mediated loss.
TTX induces ADAR2 degradation which is blocked by the proteasome inhibitor BTZ. We speculate that ADAR2 accumulated in the cytosol can be re-imported into nucleus to maintain a functional pool of nuclear ADAR2. Consistent with this, blocking proteasomal degradation of ADAR2 prevents TTX induced GluK2 up-scaling. Thus, the loss of ADAR2 and consequent reduction in GluK2 Q/R editing are necessary and sufficient for KARs up-scaling.
KARs play key roles in neuronal excitability, synaptic transmission and plasticity, and network activity (3, 35) . Moreover, KAR dysregulation is implicated in neuronal pathologies (36, 37). How KAR upscaling impacts on these pathways is an outstanding question. Our data provide novel mechanistic insight into how neuronal activity controls the surface expression and properties of KARs during homeostatic scaling that will have wide implication for neuronal function, and dysfunction in disease.
Materials and Methods
Primary neuronal cultures: Primary rat hippocampal neurones were dissected from E18 Wistar rat pups as previously described (38). Briefly neurones were dissected from E18 Wistar rats followed by trypsin dissociation and cultured for up to 2 weeks. For the first 24 h, cells were grown in plating media: Neurobasal media (Gibco) supplemented with 10% horse serum (Sigma), B27 (1x, Gibco), P/S (100 units penicillin and 0.1mg/ml streptomycin; ThermoScientific) and 5mM Glutamax (Gibco).
After 24 h, plating media was replaced with feeding media (Neurobasal containing 2mM Glutamax and lacking horse serum and P/S). For biochemistry experiments, cells were plated at a density of 500,000 per 35mm well and 250,000 per coverslip for imaging experiments.
ADAR2 cloning ADAR2 was cloned from rat neuronal cDNA and ADAR2 shRNA knockdown and knockdownrescue viruses were generated as previously described (38). ADAR2 was cloned from rat neuronal cDNA into the KpnI and XbaI sites of the vector pcDNA3 with a HA tag at its N-terminus.
Phosphomutants of ADAR2 were generated by site-directed mutagenesis. Pin1 was cloned from rat neuronal cDNA into the EcoRI and BamHI sites of the vector pEGFP-N1. To determine the level of RNA editing, BbvI (New England Biolabs) digestion was used as previously (39) . Total 20µl digestion was set up using 10µl of PCR product at 37 0 C for 2 h. All of the digested product was run on 4% agarose gel and the ethidium bromide stained bands were imaged using UV transilluminator and quantified using FIJI NIH ImageJ. To determine the level of editing in GluK2, the following formula was used: [Intensity of 376 (edited)/Intensity of (376 (edited) + 269 (unedited))]*100. The band at 76bp allowed to determine equal loading. For GluA2, [Intensity of 158
(edited)/Intensity of (158 (edited) + 94 (unedited))]*100.
Purified PCR products were also sent for sequencing to Eurofins Genomics at 4ng/µl along with the above GluK2 and GluA2 F primers, to obtain sequence chromatographs. A Leica SP7 confocal microscope was used to image the coverslips. FIJI NIH Image J was used to compress the z-stacks and analyse the mean intensity per nucleus using the DAPI channel to draw regions of interest. To calculate the percentage of cells expressing ADAR2, all the cells expressing ADAR2 were manually counted per image taken.
Statistical Analysis
Mean value were calculated for all data and all error bars show standard deviation. All statistical analysis was performed using GraphPad Prism software version 7.0 as stated. Figure 2 . Chronic suppression of network activity with TTX decreases ADAR2 levels. Figure 6 . Loss of ADAR2 during scaling is not dependent on Pin1 or ADAR2 phosphorylation f. Quantification of (E) total ADAR2 levels normalised to GAPDH from 7 independent experiments. Each TTX treated condition was normalised to their respective non-treated control. Statistical Analysis: Unpaired t-test; *<0.05, **<0.01, ***<0.00, ****<0.0001. Statistical analysis: Unpaired t-test; ns>0.05.
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